---
title: "editorial sti pregnancy"
year: 2024
month: 01
journal: "American Family Physician"
volume: "109-110"
issue: "01"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-01-editorial-sti-pregnancy.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# editorial sti pregnancy

                                                                 Editorials
                                         STIs During Pregnancy
                Patricia Carr Reese MD, MPH, AAHIVS, Lancaster General Health Physicians Comprehensive Care


Screening for and treatment of sexually transmitted infec- reported cases of primary and secondary syphilis in women
tions (STIs) is a key aspect of prenatal care. Family physi-                       increased 179%, and congenital syphilis cases increased
cians have a responsibility to initiate open and informative                       291%.14,15 The dramatic rise in congenital syphilis can further
discussions about sexual health with pregnant patients.                            be attributed to insufficient access to prenatal care and poor
Obtaining a sexual history is detailed in a previous issue of                      adherence to national screening guidelines, as discussed
American Family Physician (AFP).1                                                  in a 2020 AFP editorial.16,17 All pregnant patients should be
   The Centers for Disease Control and Prevention (CDC)                            screened in the first trimester, and patients at high risk or
and U.S. Preventive Services Task Force (USPSTF) recom-                            living in high-prevalence communities should receive repeat
mend screening for HIV, syphilis, hepatitis B, and usually                         testing at 28 weeks and delivery.18
hepatitis C at the first prenatal visit.2-5 Current guidelines                        Diagnosing syphilis requires a low threshold of suspicion
were developed based on data from cis women, but no avail-                         and a thorough history and physical examination. Although
able data suggest that recommendations should be different                         the classic syphilitic chancre is a single, sharply demarcated,
for any pregnant person. Key points of diagnosis, treatment,                       painless ulcer, only 30% of patients have this presentation.19
test of cure, and pregnancy complications for STIs are sum-                        Chancres may be hidden (e.g., in the cervix or rectum) or
marized in Table 1.2                                                               absent.19 Opt-out screening is essential because a large
                                                                                   National Institutes of Health study found that 49% of preg-
Chlamydia and Gonorrhea                                                            nant women with syphilis from 2012 to 2016 had no identi-
Chlamydia trachomatis infection is the most common                                 fiable risk factors.15
reportable STI in the United States, followed by Neisseria                            Adverse pregnancy outcomes occur in 50% to 80% of
gonorrhoeae infection.2 These two infections are usually                           pregnancies affected by syphilis.20 Treatment decreases fetal
asymptomatic.6-8 The CDC recommends testing for chla-                              risk. Penicillin is the only appropriate treatment for syph-
mydia and gonorrhea at the first prenatal visit in most                            ilis in pregnancy;​desensitization is required for patients
women younger than 25 years and in women 25 years and                              allergic to penicillin.2 Most pregnant women will not have
older who are at high risk of infection.2 Testing should be                        time to achieve the fourfold decrease in rapid plasma reagin
repeated in the third trimester for individuals at high risk.                      titer that indicates successful treatment;​the absence of this
   A nucleic acid amplification test (NAAT) for chlamydia                          decrease does not suggest treatment failure. However, a four-
and gonorrhea can be performed using vaginal or endo-                              fold increase sustained for more than two weeks raises con-
cervical swab samples or first-catch urine.2 Self collection                       cerns for reinfection or treatment failure.
of vaginal swabs is well validated.9 An NAAT using liquid-                            When syphilis is diagnosed during pregnancy, congen-
based cytology specimens from Papanicolaou smears have                             ital syphilis is presumed.17 Treatment should be provided
lower sensitivity than using endocervical or vaginal swabs.10                      immediately in conjunction with maternal-fetal medicine.
In patients with cervicitis, urine samples may miss 10% of                         Appropriate treatment does not guarantee that the fetus will
infections compared with vaginal or endocervical samples.11                        be unaffected. Infants born to mothers with syphilis during
Oropharyngeal and rectal testing for chlamydia and gon-                            pregnancy should receive a serum quantitative nontrepone-
orrhea should be considered based on the patient’s sexual                          mal test and an HIV viral load measurement and be referred
practices. Of note, urogenital testing is not a substitute for                     to a pediatric infectious disease specialist for long-term
anorectal testing because there is poor concordance in test                        monitoring, because most neonates are not born with overt
results between sites.12,13 Expedited partner treatment regu-                      signs of congenital syphilis. For syphilis, expedited partner
lations vary by state but should be used, when possible, due                       treatment recommendations are expanded to include any
to high reinfection rates. For gonorrhea and chlamydia, all                        sex or needle-sharing partners in the past 90 days.2
sex partners in the past 60 days should be treated.2
                                                                                   HIV
Syphilis                                                                           The CDC and USPSTF guidelines recommend discussing
Syphilis rates have been increasing since 2000, especially                         preexposure prophylaxis (PrEP) with patients at risk of HIV,
recently, with methamphetamine use contributing signifi-                           especially those with a recent bacterial STI.21,22 Preconcep-
cantly to incident cases among women.14 From 2015 to 2019,                         tion, during pregnancy, and the first six months postpartum

10  American
 Downloaded     Family
             from        Physician
                  the American   Family Physician website at www.aafp.org/afp.           © 2024 American AcademyVolume
                                                                                  Copyright
                                                                    www.aafp.org/afp                                     of Family Physicians.
                                                                                                                                 109, NumberFor1 theJanuary
                                                                                                                                                 ◆    private, non-
                                                                                                                                                               2024
 commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                               EDITORIALS
   TABLE 1

   STIs During Pregnancy:​Screening, Treatment, and Complications
                     Screening                                      Second-line
   Infection         modality           First-line treatment        treatment         Test of cure          Complications

   Gonorrhea         NAAT,* point-      Ceftriaxone                 Consult an        One week after        Spontaneous abortion, PPROM,
                     of-care NAAT,        < 150 kg:​500 mg IM       infectious        treatment for         preterm delivery, chorioamnio­
                     culture (resis-                                disease or STI    only oropharyn-       nitis, low-birth-weight infants
                     tance testing)       ≥ 150 kg:​1,000 mg IM     clinical expert   geal infection        Neonatal infection:​ophthalmia
                                                                                                            neonatorum (second to fifth
                                                                                                            day of life), sepsis, arthritis,
                                                                                                            meningitis, rhinitis, vagini-
                                                                                                            tis, urethritis, scalp infection
                                                                                                            at sites of previous fetal
                                                                                                            monitoring

   Chlamydia         NAAT*              Azithromycin, single        Amoxicillin,      Four weeks            PPROM, preterm delivery, still-
                                        1-g dose orally             500 mg orally     after treatment       birth, low-birth-weight infants
                                                                    three times       for urogenital        Neonatal infection:​ophthalmia
                                                                    daily for seven   infections            neonatorum (fifth to 30th day
                                                                    days                                    of life), oropharynx/respiratory
                                                                                                            (subacute, afebrile pneumonia
                                                                                                            at one to three months of age),
                                                                                                            urogenital tract, rectum

   Syphilis          Treponemal†        Primary, secondary,         —                 Treatment ≤ 24        Spontaneous abortion, fetal
                     and nontrepo-      and early latent:​peni-                       weeks:​ repeat        demise, placentomegaly, hep-
                     nemal‡ testing     cillin G benzathine, 2.4                      titers no less        atomegaly, polyhydramnios,
                                        million units IM one                          than eight weeks      ascites, nonimmune hydrops,
                                        time (consider second                         after treatment       anemia
                                        dose one week later)                          and at delivery       Early or late congenital syphilis
                                        Late latent:​penicillin G                     Treatment > 24
                                        benzathine, 2.4 million                       weeks:​ repeat
                                        units IM once per                             titers at delivery
                                        week for three weeks                          Repeat titers
                                        Neuro, otic, or ocular:​                      earlier if reinfec-
                                        aqueous crystalline                           tion or treat-
                                        penicillin G infusion, 18                     ment failure is
                                        to 24 million units per                       suspected
                                        day for 10 to 14 days

   HIV               HIV antibody/      Antiretroviral treatment    —                 —                     Vertical transmission
                     antigen

   Hepatitis B       Hepatitis B sur-   Pending additional          —                 —                     Vertical transmission
                     face antigen       testing

   Hepatitis C       Hepatitis C        Pending additional          —                 —                     Vertical transmission
                     antibody           testing

   Trichomoniasis    Not ​              Metronidazole,              Extended          —                     PPROM, preterm delivery, low-
                     recommended        500 mg orally twice         course for                              birth-weight infants
                                        per day for seven days      treatment                               Case reports of neonatal infec-
                                                                    failure                                 tion, with Trichomonas vaginalis
                                                                                                            presenting as respiratory or
                                                                                                            genital infections
                                                                                                                                    continues

   IM = intramuscularly;​NAAT = nucleic acid amplification test;​PPROM = preterm premature rupture of membranes;​STI = sexually transmitted
   infection.
   *—Urine, vaginal (clinician or patient collected), endocervical, rectal, oropharyngeal.
   †—Enzyme immunoassay, chemiluminescence immunoassay, Treponema pallidum particle agglutination test, and fluorescent treponemal
   antibody-absorption test.
   ‡—Rapid plasma reagin test and Venereal Disease Research Laboratory test.




January 2024 ◆ Volume 109, Number 1                        www.aafp.org/afp                                  American Family Physician 11
                                                                       EDITORIALS
    TABLE 1 (continued)

    STIs During Pregnancy:​Screening, Treatment, and Complications
                        Screening                                            Second-line
    Infection           modality              First-line treatment           treatment           Test of cure            Complications

    Herpes sim-         Not ​                 Suppressive treatment          —                   —                       Preterm delivery, spontaneous
    plex virus 2        recommended           (start at 36 weeks):​                                                      abortion, fetal demise
                                              acyclovir, 400 mg three                                                    Neonatal eye or skin lesions,
                                              times per day, or vala-                                                    meningoencephalitis, dis-
                                              cyclovir, 500 mg twice                                                     seminated infections, fetal
                                              per day until delivery                                                     malformations

    NAAT = nucleic acid amplification test;​IM = intramuscularly;​PPROM = preterm premature rupture of membranes;​STI = sexually transmitted
    infection.
    *—Urine, vaginal (clinician or patient collected), endocervical, rectal, oropharyngeal.
    †—Enzyme immunoassay, chemiluminescence immunoassay, Treponema pallidum particle agglutination test, and fluorescent treponemal
    antibody-absorption test.
    ‡—Rapid plasma reagin test and Venereal Disease Research Laboratory test.
    Information from reference 2.




are particularly high-risk times for HIV acquisition. PrEP                           women by testing SurePath liquid-based Pap specimens in APTIMA
                                                                                     assays. J Clin Microbiol. 2007;​45(8):​2434-2438.
with combination emtricitabine/tenofovir disoproxil fuma-
                                                                                  11. Centers for Disease Control and Prevention. Recommendations for the
rate (Truvada) is safe during pregnancy and breastfeeding.                            laboratory-based detection of Chlamydia trachomatis and Neisseria
                                                                                      gonorrhoeae—2014. MMWR Recomm Rep. 2014;​63(RR-02):​1-19.
Address correspondence to Patricia Carr Reese MD, MPH,
                                                                                  12. Dukers-Muijrers NH, Schachter J, van Liere GA, et al. What is needed to
AAHIVS, at trish.carrreese@​pennmedicine.upenn.edu. Reprints
                                                                                      guide testing for anorectal and pharyngeal Chlamydia trachomatis and
are not available from the author.
                                                                                      Neisseria gonorrhoeae in women and men? Evidence and opinion. BMC
Author disclosure:​No relevant financial relationships.                               Infect Dis. 2015;​15:​533.
                                                                                  13. Bazan JA, Carr Reese P, Esber A, et al. High prevalence of rectal gonor-
References                                                                            rhea and chlamydia infection in women attending a sexually transmit-
                                                                                      ted disease clinic. J Womens Health (Larchmt). 2015;​24(3):​182-189.
 1. Savoy M, O’Gurek D, Brown-James A. Sexual health history:​techniques
    and tips. Am Fam Physician. 2020;​101(5):​286-293.                            14. Centers for Disease Control and Prevention. Syphilis surveillance
 2. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infec-            supplemental slides, 2015-2019. July 2021. Accessed September 19,
    tions treatment guidelines, 2021. MMWR Recomm Rep. 2021;​70(4):​1-187.            2023. https://​w ww.cdc.gov/std/statistics/syphilis-supplement/syphilis-
                                                                                      surveillance-supplement-2015-2019_cleared.pdf
3. Davidson KW, Barry MJ, Mangione CM, et al. Screening for chlamydia
   and gonorrhea:​US Preventive Services Task Force recommendation                15. Trivedi S, Williams C, Torrone E, et al. National trends and reported
   statement. JAMA. 2021;​326(10):​949-956.                                           risk factors among pregnant women with syphilis in the United States,
                                                                                      2012-2016. Obstet Gynecol. 2019;​1 33(1):​27-32.
4. Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis B virus
   infection in pregnant women:​US Preventive Services Task Force reaf-           16. Lin KW. Closing primary and prenatal care gaps to prevent congenital
   firmation recommendation statement [published correction appears in                syphilis [published correction in Am Fam Physician. 2021;​103(1):​8]. Am
   JAMA. 2019;​322(11):​1 108]. JAMA. 2019;​322(4):​3 49-354.                         Fam Physician. 2020;​102(2):​78-79.
5. Owens DK, Davidson KW, Krist AH, et al. Screening for HIV infection:​          17. Adhikari EH. Syphilis in pregnancy. Obstet Gynecol. 2020;​135(5):​1121-1135.
   US Preventive Services Task Force recommendation statement. JAMA.              18. Curry SJ, Krist AH, Owens DK, et al. Screening for syphilis infection in
   2019;​321(23):​2326-2336.                                                          pregnant women:​US Preventive Services Task Force reaffirmation rec-
6. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted dis-              ommendation statement. JAMA. 2018;​320(9):​911-917.
   eases:​the case for screening. Prev Med. 2003;​36(4):​502-509.                 19. New York City Department of Health and Mental Hygiene;​New York
 7. Korenromp EL, Sudaryo MK, de Vlas SJ, et al. What proportion of epi-              City STD Prevention Training Center. The diagnosis and management
    sodes of gonorrhoea and chlamydia becomes symptomatic? Int J STD                  of syphilis:​an update and review. March 2019. Accessed August 4, 2022.
    AIDS. 2002;​1 3(2):​91-101.                                                       https://​ w ww.nycptc.org/x/Syphilis_Monograph_2019_NYC_PTC_
8. Detels R, Green AM, Klausner JD, et al. The incidence and correlates of            NYC_DOHMH.pdf
   symptomatic and asymptomatic Chlamydia trachomatis and Neisseria               20. Tsai S, Sun MY, Kuller JA, et al. Syphilis in pregnancy. Obstet Gynecol
   gonorrhoeae infections in selected populations in five countries. Sex              Surv. 2019;​74(9):​557-564.
   Transm Dis. 2011;​38(6):​503-509.                                              21. Centers for Disease Control and Prevention;​US Public Health Service.
9. Knox J, Tabrizi SN, Miller P, et al. Evaluation of self-collected samples in       Preexposure prophylaxis for the prevention of HIV infection in the
   contrast to practitioner-collected samples for detection of Chlamydia              United States—2021 update:​a clinical practice guideline. Accessed Sep-
   trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by                   tember 19, 2023. https://​w ww.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-
   polymerase chain reaction among women living in remote areas. Sex                  guidelines-2021.pdf
   Transm Dis. 2002;​29(11):​6 47-654.                                            22. Owens DK, Davidson KW, Krist AH, et al. Preexposure prophylaxis for
10. Chernesky M, Freund GG, Hook E III, et al. Detection of Chlamydia                 the prevention of HIV infection:​US Preventive Services Task Force rec-
    trachomatis and Neisseria gonorrhoeae infections in North American                ommendation statement. JAMA. 2019;​321(22):​2203-2213. ■




12 American Family Physician                                      www.aafp.org/afp                                  Volume 109, Number 1 ◆ January 2024
